On the front line in the Covid-19 crisis, players in the pharmaceutical industry need support in optimizing the management of their stocks and their supply chain. To help them face the current crisis and anticipate those that are sure to arrive, a turnkey and adapted technological solution is undoubtedly their best ally.
The Achilles heel of an industry overworked by the crisis
While it has shown formidable efficiency during the crisis, the pharmaceutical industry cannot free itself from certain political, economic and even regulatory contingencies.
In this context of health crisis, the question of sovereignty in the field of drugs arises acutely. Almost 80% of the active substances in our medicines are produced in China and India, from a small number of suppliers. These two countries do not have the only disadvantage of being particularly distant: they have both been hit hard by Covid-19, which has partly disrupted their production capacities.
This dangerous dependence has undermined our health autonomy at a crucial time. As we chained the epidemic waves, we also had to face major supply difficulties.
With its procession of factory closures and government orders banning the export of raw materials, this pandemic will have had the merit of lifting the veil on an eminently political and economic situation, which inevitably disrupts the national pharmaceutical supply chain and threatens the health of our citizens.
The general state of the drug industry is based on the pace of its scientific innovations, legal decrees, and other exogenous factors relating to epidemics, mutations and natural and social disasters. On a regular basis, new legal health standards are voted on. Faced with the implementation of these new regulations, industry players must constantly adapt and demonstrate remarkable agility and flexibility.
Finally, pharmaceutical raw materials are fragile and sometimes unstable elements, which must be transported and handled with extreme care. In addition, an important part of the international transport of medicines (import and export) is based on the airline activity. The reduction in air traffic caused by the pandemic has created great difficulties in meeting the planet’s drug needs, further complicating the already heavy logistics.
So how do you break free from this state of dangerous dependence, regain control of the present and pave the way for the long term with clarity, agility and efficiency?
The digital transformation of logistics, a breath of fresh air for the pharmaceutical industry
The automation of the logistics process, and the management of monitoring data using suitable software together form the key solution to overcome the difficulties inherent in the industry. From this transformation, a liberation?
The digitization of logistics enables optimized inventory management and an acute assessment of the progress of the supply chain. The advantage of such a system is to make the entry and exit of goods as fluid as possible, from suppliers and distributors, and to obtain an overall understanding of the market. Equipped with such a tool, the various players will be able to ensure optimized management of their stocks, and overcome any risk of shortages, thanks to increased agility and a better capacity for apprehension.
A suitable turnkey solution will improve the efficiency of logistics management at each stage of the supply chain, from the reception of raw materials to the distribution of the packaged product.
Equipped with an appropriate technological solution, industry players will be able to transport their goods optimally and at a lower cost, ensuring “grouped” shipments thanks to better knowledge of the overall state of supply. In addition, such a solution not only allows economic gain by reducing transport costs, it also reduces the company’s carbon footprint, thanks to a reduction in the number of deferred shipments.
Finally, suitable software will provide a traceability service. All goods will thus be strictly recorded in a database. This listing ensures serialization monitoring and facilitates rapid identification in the event of a fault in a series. It also makes it possible to actively contribute to the fight against the trafficking of fake medicines, a scourge of international scope.
Economic, ecological, social and societal gains … The benefits of such a digital tool are numerous. They go beyond the borders of the industry itself. Once again, innovation reveals here its irreplaceable function of going beyond the borders of a practice or the limits of an activity to bring these to ever higher levels of efficiency and quality.
The coronavirus crisis is a reminder of the strategic role of this industry, whether economic, social or political. It also reminds us of our dependence on the supply of our pharmaceutical raw materials. So let’s react: let’s redistribute the cards of this dangerous game that is hurting us, and arm ourselves to face the unpredictable.